Targeting Breast Cancer Stem Cells

Zhang, Lu; Chen, Wenmin; Liu, Suling; Chen, Ceshi

doi:10.7150/ijbs.76187

Cited by 38 publications

(21 citation statements)

References 285 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of their higher tolerability to chemotherapy, hormone therapy, and radiotherapy [ 28 ], these cells can reproduce the bulk of the tumor after a reduction in cell populations sensitive to first-line therapy, leading to disease relapse. Significant advances have been made in the identification, isolation, and characterization of BCSCs, and as a consequence, the development of new compounds targeting this small cell population are being developed [ 29 ]. However, the selection pressure of monotherapy could generate resistant BCSC clones, which is why we believe a combination therapy is more desirable.…”

Section: Discussionmentioning

confidence: 99%

Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells

Robert,

Roman Ortiz,

LaRocca

et al. 2024

Viruses

View full text Add to dashboard Cite

Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically target cancer cells. However, its potential to target BCSCs remains unclear. Here, we evaluated a Cox-2 promoter-controlled, Ad5/3 fiber-modified OAd designed to encode the human sodium iodide symporter (hNIS) in breast cancer models. To confirm the potential of OAds to target BCSCs, we employed BCSC-enriched estrogen receptor-positive (ER+) paclitaxel-resistant (TaxR) cells and tumorsphere assays. OAd-hNIS demonstrated significantly enhanced binding and superior oncolysis in breast cancer cells, including ER+ cells, while exhibiting no activity in normal mammary epithelial cells. We observed improved NIS expression as the result of adenovirus death protein deletion. OAd-hNIS demonstrated efficacy in targeting TaxR BCSCs, exhibiting superior killing and hNIS expression compared to the parental cells. Our vector was capable of inhibiting tumorsphere formation upon early infection and reversing paclitaxel resistance in TaxR cells. Importantly, OAd-hNIS also destroyed already formed tumorspheres seven days after their initiation. Overall, our findings highlight the promise of OAd-hNIS as a potential tool for studying and targeting ER+ breast cancer recurrence and metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells

Robert,

Roman Ortiz,

LaRocca

et al. 2024

Viruses

View full text Add to dashboard Cite

show abstract

“…Luminal A is more frequent than luminal B and has a lower histological grade as well as a superior prognosis [ 29 ], while HER2 is more aggressive than luminal B [ 30 ]. The basal-like subtype has a high Ki67 index and exhibits phenotypic similarities with TNBC [ 31 ]. As TNBC is more aggressive and lacks a signature receptor, TNBC has a greater recurrence probability and a worse 5-year survival rate compared to other types of BC.…”

Section: Breast Cancer and Drugsmentioning

confidence: 99%

KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

Li,

Wang,

Leung

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Breast cancer (BC) is the most frequent malignant cancer diagnosis and is a primary factor for cancer deaths in women. The clinical subtypes of BC include estrogen receptor (ER) positive, progesterone receptor (PR) positive, human epidermal growth factor receptor 2 (HER2) positive, and triple-negative BC (TNBC). Based on the stages and subtypes of BC, various treatment methods are available with variations in the rates of progression-free disease and overall survival of patients. However, the treatment of BC still faces challenges, particularly in terms of drug resistance and recurrence. The study of epigenetics has provided new ideas for treating BC. Targeting aberrant epigenetic factors with inhibitors represents a promising anticancer strategy. The KDM5 family includes four members, KDM5A, KDM5B, KDM5C, and KDMD, all of which are Jumonji C domain-containing histone H3K4me2/3 demethylases. KDM5 proteins have been extensively studied in BC, where they are involved in suppressing or promoting BC depending on their specific upstream and downstream pathways. Several KDM5 inhibitors have shown potent BC inhibitory activity in vitro and in vivo, but challenges still exist in developing KDM5 inhibitors. In this review, we introduce the subtypes of BC and their current therapeutic options, summarize KDM5 family context-specific functions in the pathobiology of BC, and discuss the outlook and pitfalls of KDM5 inhibitors in this disease.

show abstract

“…NRF2, a key transcriptional factor in the redox system, regulates the anti-oxidative defence at multiple levels (75). Under physiological conditions, NRF2 is inactivated via interaction with Kelch-like ECH-associated protein 1.…”

Section: Anti-oxidative Activity Of Ginsenosidesmentioning

confidence: 99%

Protective effects of ginseng and ginsenosides in the development of osteoarthritis (Review)

Chen

Hu²,

Liao

2023

Exp Ther Med

View full text Add to dashboard Cite

Osteoarthritis (OA) is a chronic inflammatory joint disease. Traditional chinese medicine provides a resource for drug screening for OA treatment. Ginseng and the associated bioactive compound, ginsenosides, may reduce inflammation, which is considered a risk factor for the development of OA. Specifically, ginsenosides may exhibit anti-inflammatory and anti-oxidative stress activities, and inhibit extracellular matrix degradation by suppressing the NF-κB and MAPK signaling pathways. Notably, specific ginsenosides, such as compound K and Rk1, may physically interact with IκB kinase and inhibit the associated phosphorylation. Thus, ginsenosides exhibit potential as therapeutic candidates in the management of OA. However, the low water solubility limits the clinical applications of ginsenosides. Numerous effective strategies have been explored to improve bioavailability; however, further investigations are still required. Contents1. Introduction 2. Protective effects of ginseng and ginsenosides against OA development 3. Anti-inflammatory properties of ginsenosides 4. Anti-oxidative activity of ginsenosides 5. Inhibitory activity of ginsenosides against ECM degradation 6. Pharmacokinetic properties of ginsenosides 7. Clinical perspectives 8. Conclusions

show abstract

Targeting Breast Cancer Stem Cells

Cited by 38 publications

References 285 publications

Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells

Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells

KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

Protective effects of ginseng and ginsenosides in the development of osteoarthritis (Review)

Contact Info

Product

Resources

About